期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 62, 期 8, 页码 1303-1313出版社
SPRINGER
DOI: 10.1007/s00262-013-1430-x
关键词
Hu14.18-IL2; Immunocytokine; Tumor-infiltrating leukocytes; NKG2D; Neuroblastoma
资金
- National Institutes of Health [CA032685, CA87025, CA166105, CA14520, GM067386]
- Department of Defense [W81XWH-08-1-0559]
- Midwest Athletes for Childhood Cancer Fund
- Crawdaddy Foundation
- Evan Dunbar Foundation
- University of Wisconsin-Madison Institute for Clinical and Translational Research (ICTR) TL1 Training Grant [1TL1RR025013-01]
Hu14.18-IL2 is an immunocytokine (IC) consisting of human IL-2 linked to hu14.18 mAb, which recognizes GD2 disialoganglioside. Phase II clinical trials of intravenous-hu14.18-IL2 (IV-IC) in neuroblastoma and melanoma are underway, and have already demonstrated activity in neuroblastoma. In our Phase II trial, lower neuroblastoma burden at the time of treatment was associated with a greater likelihood of clinical response to IV-IC. We have previously shown that intratumoral-hu14.18-IL2 (IT-IC) compared to IV-IC results in enhanced local and systemic antitumor activity in tumor-bearing mice. We utilized a mouse model to investigate the impact of tumor burden on hu14.18-IL2 treatment efficacy in IV- versus IT-treated animals. Studies presented here describe the analyses of tumor burden at the initiation of treatment and its effects on treatment efficacy, survival, and tumor-infiltrating leukocytes in A/J mice bearing subcutaneous NXS2 neuroblastoma. We show that smaller tumor burden at treatment initiation is associated with increased infiltration of NK and CD8+ T cells and increased overall survival. NXS2 tumor shrinkage shortly after completion of the 3 days of hu14.18-IL2 treatment is necessary for long-term survival. This model demonstrates that tumor size is a strong predictor of hu14.18-IL2-induced lymphocyte infiltration and treatment outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据